Disease state, age, sex, and post-mortem time-dependent expression of proteins in AD vs. control frontal cortex brain samples

Current Alzheimer Research

Volumn 5, Issue 6, 2008, Pages 562-571

  Muller T ^a   Jung, K ^b   Ullrich, A ^a   Schrotter A ^a   Meyer, H E ^a   Stephan, C ^a   Egensperger, R ^c   Marcus, K ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; ASPARTATE AMINOTRANSFERASE; BCL 2 ASSOCIATED TRANSCRIPTION FACTOR 1; BRAIN PROTEIN; DIHYDROPYRIMIDASE RELATED PROTEIN 2; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE A; HEAT SHOCK PROTEIN 70; HEMOGLOBIN; METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE (ACYLATING); NEUROFILAMENT M PROTEIN; PROTEIN NIPSNAP2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; UNIQUITIN CARBOXYL TERMINAL HYDROLASE ISOZYME L1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SCORING SYSTEM;

AGING; ALZHEIMER DISEASE; DATA INTERPRETATION, STATISTICAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NERVE TISSUE PROTEINS; POSTMORTEM CHANGES; PREFRONTAL CORTEX; SEX CHARACTERISTICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TRYPSIN;

EID: 58049221284     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508786898488     Document Type: Article

References (42)

1. Schonberger SJ, Edgar PF, Kydd R, Faull RL and Cooper GJ. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1: 1519-1528 (2001).
2. Tsuji T, Shiozaki A, Kohno R, Yoshizato K and Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 27: 1245-1253 (2002).
3. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P, et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118: 140-146 (2003).
4. Liao L, Cheng D, Wang J, Duong DM, Losik TG, Gearing M, et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279: 37061-37068 (2004).
5. Crecelius A, Gotz A, Arzberger T, Frohlich T, Arnold GJ, Ferrer I, et al. Assessing quantitative post-mortem changes in the gray matter of the human frontal cortex proteome by 2-D DIGE. Proteomics 8: 1276-1291 (2008).
6. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, et al. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 66: 35-46 (2007).
7. Franzen B, Yang Y, Sunnemark D, Wickman M, Ottervald J, Oppermann M, et al. Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome. Proteomics 3: 1920-1929 (2003).
8. Li X, Greenwood AF, Powers R and Jope RS. Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Neurobiol Aging 17: 115-122 (1996).
9. Li J, Gould TD, Yuan P, Manji HK and Chen G. Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology 28: 1017-1025 (2003).
10. Liu X and Brun A. Synaptophysin immunoreactivity is stable 36 h postmortem. Dementia 6: 211-217 (1995).
11. Schwab C, Bondada V, Sparks DL, Cahan LD and Geddes JW. Postmortem changes in the levels and localization of microtubule-associated proteins (tau, MAP2 and MAP1B) in the rat and human hippocampus. Hippocampus 4: 210-225 (1994).
12. Siew LK, Love S, Dawbarn D, Wilcock GK and Allen SJ. Measurement of pre- and post-synaptic proteins in cerebral cortex: effects of post-mortem delay. J Neurosci Methods 139: 153-159 (2004).
13. Irving EA, McCulloch J and Dewar D. The effect of postmortem delay on the distribution of microtubule-associated proteins tau, MAP2, and MAP5 in the rat. Mol Chem Neuropathol 30: 253-271 (1997).
14. Sorimachi Y, Harada K and Yoshida K. Involvement of calpain in postmortem proteolysis in the rat brain. Forensic Sci Int 81: 165-174 (1996).
15. Braak H and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259 (1991).
16. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486 (1991).
17. Klose J and Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 16: 1034-1059 (1995).
18. Stuhler K, Pfeiffer K, Joppich C, Stephan C, Jung K, Muller M, et al. Pilot study of the human proteome organisation brain proteome project: Applying different 2-DE techniques to monitor proteomic changes during murine brain development. Proteomics 6: 4899-4913 (2006).
19. Heukeshoven J and Dernick R. Simplified method for silver staining of proteins in polyacrylamide gels and the mechanism of silver staining. Electrophoresis 6: 103-112 (1985).
20. Jung K, Gannoun A, Sitek B, Meyer HE, Stuhler K, Urfer W, et al. Analysis of dynamic protein expression data State J 3: 99-111 (2005).
21. Storey JD. The positive false discovery rate: a bayesian interpretation and the q-value. Ann Appl Stat 31: 2013-2035 (2003).
22. Marcus K, Immler D, Sternberger J and Meyer HE. Identification of platelet proteins separated by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis 21: 2622-2636 (2000).
23. Lohaus C, Nolte A, Bluggel M, Scheer C, Klose J, Gobom J, et al. Multidimensional chromatography: a powerful tool for the analysis of membrane proteins in mouse brain. J Proteome Res 6: 105-113 (2007).
24. Perkins DN, Pappin DJ, Creasy DM and Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data 1. Electrophoresis 20: 3551-3567 (1999).
25. Sergeant N, Wattez A, Galvan-valencia M, Ghestem A, David JP, Lemoine J, et al. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience 117: 293-303 (2003).
26. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, et al. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11: 153-164 (2007).
27. Geula C, Nagykery N, Nicholas A and Wu CK. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 67: 309-18 (2008).
28. Lehericy S, Hirsch EC, Cervera-Pierot P, Hersh LB, Bakchine S, Piette F, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 330: 15-31 (1993).
29. Ko LW, Sheu KF, Thaler HT, Markesbery WR and Blass JP. Selective loss of KGDHC-enriched neurons in Alzheimer temporal cortex: does mitochondrial variation contribute to selective vulnerability? J Mol Neurosci 17: 361-369 (2001).
30. Zatta P, Lain E and Cagnolini C. Effects of aluminum on activity of krebs cycle enzymes and glutamate dehydrogenase in rat brain homogenate. Eur J Biochem 267: 3049-3055 (2000).
31. Fountoulakis M, Hardmeier R, Hoger H and Lubec G. Postmortem changes in the level of brain proteins. Exp Neurol 167: 86-94 (2001).
32. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532 (2002).
33. Gong B and Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders 1. Drug News Perspect 20: 365-370 (2007).
34. Beard CM, Kokmen E, O'Brien PC, Ania BJ and Melton LJ, III. Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann Epidemiol 7: 219-224 (1997).
35. Peers C, Pearson HA and Boyle JP. Hypoxia and Alzheimer's disease. Essays Biochem 43: 153-164 (2007).
36. Pandav RS, Chandra V, Dodge HH, DeKosky ST and Ganguli M. Hemoglobin levels and Alzheimer disease: an epidemiologic study in India. Am J Geriatr Psychiatry 12: 523-526 (2004).
37. Yoo BC, Seidl R, Cairns N and Lubec G. Heat-shock protein 70 levels in brain of patients with down syndrome and Alzheimer's disease. J Neural Transm Suppl 57: 315-322 (1999).
38. Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res 29: 1287-1297 (2004).
39. Wakutani Y, Urakami K, Shimomura T and Takahashi K. Heat shock protein 70 mRNA levels in mononuclear blood cells from patients with dementia of the Alzheimer type. Dementia 6: 301-305 (1995).
40. Soucek T, Cumming R, Dargusch R, Maher P and Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39: 43-56 (2003).
41. Kim SK, Cho SM, Lee IB, Lee YH, Kang JH, Choi JH, et al. In vitro assay of neurofilament light chain self-assembly using truncated mutants. J Neurosci Methods 161: 199-204 (2007).
42. Wang J, Tung YC, Wang Y, Li XT, Iqbal K, Grundke-Iqbal I, et al. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett 507: 81-87 (2001).